NCT04864821 2021-05-06
Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Shenzhen Second People's Hospital